Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer

2021 ◽  
Author(s):  
Alia Ghoneum ◽  
Sameh Almousa ◽  
Bailey Warren ◽  
Ammar Yasser Abdulfattah ◽  
Junjun Shu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Tumor Microenvironment ◽  
Clinical Value ◽  
Platinum Resistant

scholarly journals Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer

2020 ◽  
Author(s):  
Yan Rong ◽  
Li Li
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Data ◽  
First Line ◽  
Clinical Value ◽  
Platinum Sensitivity ◽  
Platinum Sensitive ◽  
Platinum Resistant ◽  
Line Chemotherapy ◽  
Sensitive Group

Abstract Objectives: To assess the clinical value of early clearance of HE4 and CA125 for platinum sensitivity and prognosis in patients with ovarian cancer.Method: HE4 and CA125 value including clinical data of 89 patients with ovarian cancer were collected. The clearance of HE4 and CA125 were assessed base on the platinum sensitivity, two-year PFS, PFS and OS.Results: 16 patients were classified as platinum resistant and 73 as platinum sensitive according to the response to platinum-base chemotherapy. When HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle chemotherapy, it gave the highest AUC of 0.788, with 100% of sensitivity and 57.5% of specificity respectively between platinum resistant and platinum sensitive group. In addition, 59 patients were classified as two-year PFS group and 30 as not achieved two-year PFS group according to obtaining two-year PFS or not. It gave the highest AUC of 0.730, with 83.3% of sensitivity and 62.7% of specificity respectively when HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle. The prolonged PFS and OS were significantly associated by the clearance of HE4 after 3rd cycle chemotherapy (p<0.0001, p<0.0001) as well as CA125 after 1st cycle chemotherapy (p<0.0001, p<0.0001).Conclusions: Our data suggested that the early clearance of HE4 and CA125 could predict platinum response and prognosis in patients with ovarian cancer. Monitoring the HE4 and CA125 during first-line chemotherapy might be helpful in predicting platinum sensitivity and risk to progress and relapse.

scholarly journals Early clearance of serum HE4 and CA125 in predicting platinum sensitive and prognosis in epithelial ovarian cancer

2020 ◽  
Author(s):  
Yan Rong ◽  
Li Li
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Data ◽  
First Line ◽  
Clinical Value ◽  
Platinum Sensitivity ◽  
Platinum Sensitive ◽  
Platinum Resistant ◽  
Line Chemotherapy ◽  
Sensitive Group

Abstract Objectives: To assess the clinical value of early clearance of HE4 and CA125 for platinum sensitive and prognosis in patients with ovarian cancerMethod: HE4 and CA125 value including clinical data of 89 patients with ovarian cancer were collected. The clearance of HE4 and CA125 were assessed base on the platinum sensitivity, two-year PFS, PFS and OS.Results: 16 patients were classified as platinum resistant and 73 as platinum sensitive according to the response to platinum-base chemotherapy. when HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle chemotherapy, it gave the highest AUC of 0.788, with 100% of sensitivity and 57.5% of specificity respectively between platinum resistant and platinum sensitive group. In addition, 59 patients were classified as two-year PFS group and 30 as not achieved two-year PFS group according to obtaining two-year PFS or not. It gave the highest AUC of 0.730, with 83.3% of sensitivity and 62.7% of specificity respectively when HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle. The prolonged PFS and OS were significantly associated by the clearance of HE4 after 3rd cycle chemotherapy (p < 0.0001, p < 0.0001) as well as CA125 after 1st cycle chemotherapy (p < 0.0001, p < 0.0001).Conclusions: Our data suggest that the early clearance of HE4 and CA125 could predict platinum response and prognosis in patients with ovarian cancer. Monitoring the HE4 and CA125 during first-line chemotherapy might be helpful in predicting platinum sensitive and risk to progress and relapse.

scholarly journals Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Yan Rong ◽  
Li Li
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Data ◽  
First Line ◽  
Clinical Value ◽  
Platinum Sensitivity ◽  
Platinum Sensitive ◽  
Platinum Resistant ◽  
Line Chemotherapy ◽  
Sensitive Group

Abstract Objectives To assess the clinical value of early clearance of HE4 and CA125 for platinum sensitivity and prognosis in patients with ovarian cancer. Method HE4 and CA125 value including clinical data of 89 patients with ovarian cancer were collected. The clearance of HE4 and CA125 were assessed base on the platinum sensitivity, two-year PFS, PFS and OS. Results Sixteen patients were classified as platinum resistant and 73 as platinum sensitive according to the response to platinum-base chemotherapy. When HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle chemotherapy, it gave the highest AUC of 0.788, with 100% of sensitivity and 57.5% of specificity respectively between platinum resistant and platinum sensitive group. In addition, 59 patients were classified as two-year PFS group and 30 as not achieved two-year PFS group according to obtaining two-year PFS or not. It gave the highest AUC of 0.730, with 83.3% of sensitivity and 62.7% of specificity respectively when HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle. The prolonged PFS and OS were significantly associated by the clearance of HE4 after 3rd cycle chemotherapy (p< 0.0001, p< 0.0001) as well as CA125 after 1st cycle chemotherapy (p< 0.0001, p< 0.0001). Conclusions Our data suggested that the early clearance of HE4 and CA125 could predict platinum response and prognosis in patients with ovarian cancer. Monitoring the HE4 and CA125 during first-line chemotherapy might be helpful in predicting platinum sensitivity and risk to progress and relapse.

scholarly journals Asporin Is Highly Expressed in CAFs of High Grade Serous Ovarian Cancinoma Patients and Predicts Poor Prognosis

2021 ◽  
Author(s):  
Lili Wang ◽  
Xiangrong Zheng ◽  
Junhua Zhang ◽  
Wenwen Zhang ◽  
Yan Huang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Survival Analysis ◽  
Tumor Microenvironment ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
High Grade ◽  
Clinical Value ◽  
Positive Expression

Abstract Background: Tumor microenvironment is widely considered as a critical factor influencing prognosis of ovarian cancer patients. To further improve the unsatisfied clinical outcome of ovarian cancer patients, it is desperately needed to explore biomarkers with potential clinical value of ovarian cancer. Asporin (ASPN), as a member of the proteoglycan family in tumor microenvironment, has been proved to play a vital role in cancer progression by binding with CD44 receptor. However, there is still no report about the research of Asporin in ovarian cancer. The purpose of the present study was to explore the expression and prognostic significance of Asporin in high grade serous ovarian cancinoma(HGSOC). Methods: The expression level of Asporin and CD44 in 85 formalin fixed paraffin embedded (FFPE) samples of 85 HGSOC patients was detected by immunohistochemistry. The association between the expression of the two biomarkers and the clinicopathologic factors of HGSOC was assessed by χ² test. The survival analyses were performed by Kaplan-Meier.Results: Asporin was mainly expressed in CAFs of 85 HGSOC patients, while CD44 was mainly expressed on membrane of tumor cells. The positive rates of Asporin, CD44, and Asporin /CD44 co-expression were 43.53% (37/85), 34.12% (29/85) and 28.23% (24/85) in 85 HGSOC tissues, respectively. There were close associations between Asporin, CD44, Asporin/CD44 expression and CA125 level of blood, tumor differentiation, FIGO staging, chemoresistance of HGSOC patients. Further, univariate survival analysis showed that positive expression of Asporin and positive Asporin/CD44 co-expression of HGSOC indicated poor clinical outcomes, and multivariate survival analysis suggested that positive expression of Asporin and positive Asporin/CD44 co-expression were independent prognostic factors for disease–free survival (DFS) and overall survival (OS) of HGSOC patients, respectively.Conclusion: Asporin was mainly expressed in CAFs of HGSOC patients. High expression of Asporin may identify a subgroup of HGSOC patients with more chemoresistance clinicopathological features and may be a potential prognostic predictor and therapeutic target for HGSOC patients.

A molecular signature for identification of platinum resistant ovarian cancer

2008 ◽  
Vol 68 (S 01) ◽  
Author(s):  
T Fehm ◽  
M Bonin ◽  
J Hoffmann ◽  
K Sotlar ◽  
E Solomayer ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Molecular Signature ◽  
Platinum Resistant
Sign in / Sign up

Export Citation Format

Share Document